



KONGERIKET NORGE
The Kingdom of Norway

Bekreftelse på patentsøknad nr
Certification of patent application no

▽
20035745

▷ Det bekreftes herved at vedheftede dokument er nøyaktig utskrift/kopi av ovennevnte søknad, som opprinnelig inngitt 2003.12.19

▷ *It is hereby certified that the annexed document is a true copy of the above-mentioned application, as originally filed on 2003.12.19*

2005.02.03

Line Reum

Line Reum
Saksbehandler





Dig utfylt skjema sendes til adressen nedenfor. Vennligst ikke heft sammen sidene.
 er om at blankettene utfylles *maskinelt* eller ved bruk av *blokkbokstaver*. Skjema for
 iling på datamaskin kan lastes ned fra www.patentstyret.no.

Alm. tilgj 20 JUN 2005
 KO
 CO7C
 1a-e

Søker: Den som søker om patent blir også innehaver av en eventuell rettighet. (Må fylles ut)

Forbrukers navn (forbruker hvis søker er person):

Amersham Health AS

Etternavn (hvis søker er person):

PATENTSTYRET

☒ Kryss av hvis søker tidligere har vært kunde hos Patentstyret.

Oppgi gjerne kundennummer:

03-12-19*20035745

Adresse:

Nycoveien 1-2

Postboks 4220 Nydalen

Postnummer:

0401

Poststed:

Oslo

Land:

Norge

☐ Kryss av hvis flere søkere er angitt i medfølgende skjema eller på eget ark.

☐ Kryss av hvis søker(ne) utfører mindre enn 20 årverk (se veiledning).

☐ Kryss av hvis det er vedlagt erklæring om at patentsøker(ne) innehar retten til oppfinnelsen.

Kontaktinfo: Hvem skal Patentstyret henvende seg til? Oppgi telefonnummer og eventuelt referanse.

Fornavn til kontaktperson for fullmektig eller søker:

Tove Aas

Etternavn:

Helge

Telefon:

2 3 1 8 5 5 7 5

Referanse (maks. 30 tegn):

PN03101-NO

Evt. adresse til kontaktperson:

Amersham Health AS

Nycoveien 1-2, Postboks 4220 Nydalen

Postnummer:

0401

Poststed:

Oslo

Land:

Norge

Fullmektig: Hvis du ikke har oppnevnt en fullmektig, kan du gå til neste punkt.

Forbrukers navn (forbruker hvis fullmektig er person):

Amersham Health AS

Etternavn (hvis fullmektig er person):

☒ Kryss av hvis fullmektig tidligere har vært kunde hos Patentstyret.

Oppgi gjerne kundennummer:

Adresse:

Nycoveien 1-2

Postboks 4220 Nydalen

Postnummer:

0401

Poststed:

Oslo

Land:

Norge

Oppfinner: Oppfinneren skal alltid oppgis, selv om oppfinner og søker er samme person.

Oppfinners fornavn:

Vidar

Etternavn:

Olaisen

☐ Kryss av hvis oppfinner tidligere har vært kunde hos Patentstyret.

Oppgi gjerne kundennummer:

Adresse:

Amersham Health Lindesnes Fabrikker

Postnummer:

4510

Poststed:

Spangereid

Land:

Norge

☐ Kryss av hvis flere oppfinnere er angitt i medfølgende skjema eller på eget ark.

ADRESSE

Postboks 8160 Dep.
 Københavngaten 10
 00333 Oslo

TELEFON

22 38 73 00

TELEFAKS

22 38 73 01

BANKGIRO

8276.01.00192

ORGANISASJONSNR.

971526157.MVA



PATENTSTYRET®

Styret for det industrielle rettsvern

SØKNAD 3.1 AV 2

FLERE SØKERE

FLERE OPPFINNERE

PRIORITETER

VEILEDNING



søknad om patent

Tittel: Gi en kort benevnelse eller tittel for oppfinnelsen, ikke over 256 tegn, inkludert mellomrom.

Tittel:

Prosess

PCT: Fylls bare ut hvis denne søknaden er en videreføring av en tidligere innlevert internasjonal søknad (PCT).

Inngivelsesdato (åååå.mm.dd):

Søknadsnummer:

PCT-søknadens dato og nummer:

PCT

/

Prioritetskrav: Hvis du ikke har søkt om denne oppfinnelsen tidligere i et annet land eller i Norge, kan du gå videre til neste punkt.

Prioritet kreves på grunnlag av tidligere innlevert søknad i Norge eller utlandet:

Inngivelsesdato (åååå.mm.dd):

Landkode:

Søknadsnummer:

Opplysninger om tidligere søknad. Ved flere krav skal tidligste prioritet angis her:

☐ Flere prioritetskrav er angitt i medfølgende skjema, eller på eget ark.

Mikroorganisme: Fylls bare ut hvis oppfinnelsen omfatter en mikroorganisme.

Søknaden omfatter en kultur av mikroorganisme. Deponeringssted og nummer må oppgis:

Deponeringssted og nummer (benytt gjerne eget ark).

☐ Prøve av kulturen skal bare utleveres til en særlig sakkyndig.

Avdekt/utskilt: Hvis du ikke har søkt om patent i Norge tidligere, kan du gå videre til neste punkt.

Søknaden er avdekt eller utskilt fra tidligere levert søknad i Norge:

Dato (åååå.mm.dd):

Søknadsnummer:

☐ Avdekt søknad

Informasjon om opprinnelig

☐ Utskilt søknad

søknad/innsendt tilleggsmateriale

Annet:
☒ Søknaden er også levert per telefaks.

Oppgi dato (åååå.mm.dd):

2 0 0 3 1 2 1 9

☐ Jeg har bedt om forundersøkelse.

Oppgi nr (årstall - nummer - bokstøv):

Vedlegg: Angi hvilken dokumentasjon av oppfinnelsen du legger ved, samt andre vedlegg.

☐ Eventuelle tegninger i to eksemplarer

Oppgi antall tegninger:

☒ Beskrivelse av oppfinnelsen i to eksemplarer

☒ Patentkrav i to eksemplarer

☒ Fullmaktsdokument(er)

☐ Sammenheng på norsk i to eksemplarer

☐ Overdragsesdokument(er)

☐ Dokumentasjon av eventuelle prioritetskrav (prioritetsbevis)

☐ Erklæring om retten til oppfinnelsen

☐ Oversettelse av internasjonal søknad i to eksemplarer (kun hvis PCT-felt over er fylt ut)

Dato/underskrift: Sjekk at du har fylt ut punktene under "Søker", "Oppfinner" og "Vedlegg". Signer søknaden.

Sted og dato (blokkbokstaver):

Signatur:

Oslo, 19. desember 2003

Navn i blokkbokstaver:

Tove Aas Helge

 NB! Søknadsavgiften vil bli fakturert for alle søknader (dvs. at søknadsavgiften ikke skal følge søknaden).
 Betalingsfrist er ca. 1 måned, se faktura.

PATENTSTYRET®
 Styret for det industrielle rettsvern

SØKNAD s. 2 av 2

1e

PATENTSTYRET

03-12-19*20035745

Title: Process

5 The present invention provides an improved process for the production of Diethylenetriaminepentaacetic acid-bis(anhydride) (DTPA-bis(anhydride)). DTPA-bis(anhydride) is an important intermediate used in the production of drug substances e.g. for therapy and diagnosis. One such class of commercial products are chelants (chelating agents). Chelants such as DTPA-bis-methylamide and DTPA-bis (2-methoxyethylamide) are useful as sequestering agents e.g. for metal
10 detoxification of living humans and animals and non-living matter and as additives to a wide variety of products. Chelants are also well known as intermediates for the production of metal chelates. Chelates of paramagnetic metals such as gadolinium find their use as contrast agents for Magnetic Resonance Imaging (MRI). Examples
15 of commercial products useful as contrast agents for MRI are Omniscan™ of Amersham Health AS and Optimark™ of Mallinckrodt, Inc.

Processes for the for the production of DTPA-bis(anhydride) are well known in the state of art.

20

US patent 3660388 teaches a process for the production of bis-dioxo-morpholine derivatives. These derivatives correspond to bis-anhydrides of alkylene amine carboxylic acids such as the bis-anhydrides of EDTA and DTPA. Specifically example 9 of this patent teaches the production of N,N-bis(β -[2,6-dioxo-morpholinyl(4)]-ethyl)-N-carboxymethylamine, hereinafter denoted DTPA-bis(anhydride) from DTPA, acetic acid anhydride and pyridine. The reactants are
25 stirred for 48 hours at 60°C or for 5 minutes at 125°C. The amount of pyridine is about 6.5 moles per mole DTPA.

30

US patent 4822594 teaches in Example 1 the preparation of DTPA bis(anhydride) where DTPA is mixed with anhydrous pyridine and acetic anhydride is added. The reaction runs for 20 hours at 65°C. The amount of pyridine is about 6.2 moles per mole DTPA.

35

US patent 4698263, in col. 12 lines 1 to 7, and US patent 4707453, in col. 11 lines 40 to 46, both describe the same preparation of DTPA -bis(anhydride) from DTPA, acetic acid anhydride and pyridine. The reaction is run for 18 hours at reflux

temperature under a N₂ atmosphere. The amount of pyridine is about 7.5 moles per mole DTPA.

EP 0183760 B1 teaches in Example 1, i), (a) the formation of DTPA -bis(anhydride) from DTPA, acetic acid anhydride and pyridine. The reaction is run for 24 hours at 55 °C. The amount of pyridine is about 6.3 moles per mole DTPA.

It is known from the state of art that pyridine is toxic and relatively expensive and that there is a desire to reduce the amount of pyridine to a minimum, see US patent 5 508 388, col. 3, lines 23 to 27. It is likewise a desire to use a minimum number of reactants, hence the addition of acetonitrile as used in US patent 5 508 388 is not desirable. Acetonitrile is poisonous and should be avoided whenever possible.

The object with this invention is hence to provide a process for the production of DTPA -bis(anhydride) which involves a minimum of reactants. In particular the use of toxic reactants should be avoided or reduced to a minimum. It is likewise a desire to reduce the use of costly reactants to a minimum. At the same time it is important to maintain a high yield, to keep the reaction time and temperature within controllable limits and to obtain a product that can be readily used in the next process step. The product should preferably be obtained without time-consuming purification or in a form that can be easily purified for sale or a state feasible for further processing.

It has surprisingly been found that DTPA-bis(anhydride) can be produced by reacting DTPA with acetic anhydride in pyridine under elevated temperature where the molar amount of pyridine is equal to or less than 6 times the molar amount of DTPA. Notably the use of acetonitrile is avoided and the amount of pyridine is reduced under the level known from the prior art when DTPA is reacted with acetic anhydride and pyridine alone.

The present invention is defined in the patent claims. Specific details in carrying out the invention are evident from the specific examples 1 to 3 below.

Production of chelants useful in industry and in particular as therapeutics and diagnostics are described in example 4 herein. The chelants find use as sequestering agents e.g. for metal detoxification of living humans and animals and non-living matter and as additives to a wide variety of products.

The chelant DTPA-BMA of example 4 when chelated with Gd^{3+} is the active substance in the commercially available MR (Magnetic Resonance) contrast medium Omniscan™ of Amersham Health AS. The production of DTPA-BMA and Gd DTPA-BMA is further described in US patents 4859451, 4687659 and 5087439 that are hereby incorporated by reference.

The chelant versetamide (DTPA-bis(2-methoxyethylamide)) when chelated with Gd^{3+} is the active substance in the commercially available MR contrast medium Optimark™ of Mallinckrodt, Inc. The production of Gadoversetamide is described in US patent 5508388.

US patent 3660388 teaches that the bis(anhydrides) are also useful in the curing of epoxy groups containing organic compounds.

In its broadest aspect the invention thus relates to a process for the production of DTPA-bis(anhydride) by reaction of DTPA with acetic anhydride in pyridine under elevated temperature and where the amount of pyridine is reduced relative to the processes known from the state of art. The ratio of the molar amount of pyridine to the molar amount of DTPA shall be equal or less to 6.

In a preferred aspect of the invention the ratio of molar amount of pyridine to the molar amount of DTPA is significantly less than 6, for example 5 or 4 or more specifically is equal to or less than 3. It is found that the reaction rate becomes only insignificantly lower at a rate of 3 compared with a rate of 8.1, and is well within the acceptable area for an industrial process. The content of un-reacted DTPA remains low.

In a further preferred aspect of the invention the ratio of molar amount of pyridine to the molar amount of DTPA is significantly less than 3, for example about 2 or more specifically is equal to or less than 1. Even at this low molar rate the reaction rate is acceptable as well as is the content of un-reacted DTPA. It is even possible to run the process at a ratio of 0.5, however at this ratio the reaction rate seems to be lower.

The molar amount of acetic anhydride could also be optimized relative to the molar amounts of pyridine and DTPA. The stoichiometric amount is 2 moles acetic anhydride per mole DTPA, but it appears that acetic anhydride should be added in

excess, more than 7 times the molar amount of DTPA is feasible. More preferred is a molar amount of 7 to 5 times the molar amount of DTPA, and even more preferred an amount between 5 and 3 times the molar amount of DTPA. The optimum amount seems to be about 3 moles acetic anhydride per mole DTPA, although an amount only slightly higher than the stoichiometric amount of 2 moles is workable.

A high molar excess of acetic anhydride relative to the pyridine and DTPA content seems to lead to a decrease in the reaction rate. Without being bound to theory, one can assume that this is due to a dilution effect for the pyridine and DTPA reagents. A dilution effect seems to be most pronounced at lower pyridine concentrations.

Hence, in a specifically preferred aspect a molar amount of acetic anhydride of about 3 times the molar amount of DTPA is used.

In a particularly preferred aspect of the invention the molar amount of acetic anhydride is about 3 times the molar amount of DTPA and the amount of pyridine is from 3 times to approximately 1 time the molar amount of DTPA.

The reaction temperature also has impact on the overall reaction rate in the production of DTPA-bis(anhydride) from DTPA. Conventionally this reaction is run at a temperature from 60°C to 70°C. It has been found that when the process is run at 80°C, the reaction rate increases significantly without an increase in the impurity level. The impurity level is even decreased when the process is run at approximately 80°C.

In a further aspect of the invention the process for the production of a DTPA-bis(anhydride) is performed at a reaction temperature of above 65°C, more preferred above 70°C and even more preferred at 80°C or above. In a specifically preferred aspect the reaction temperature is approximately 80°C.

In a particularly preferred aspect of the invention the molar amount of acetic anhydride is about 3 times the molar amount of DTPA and the amount of pyridine is from 3 times to approximately 1 time the molar amount of DTPA when the process is run at a temperature of about 80°C.

The invention will now be illustrated further with reference to the following non-limiting examples.

The abbreviations have the following meaning:

NIR – Near Infra Red Spectroscopy

DTPA – Diethylenetriaminepentaacetic acid

5 BMA – Bismethylamine

MMA – Monomethylamine

h - Hour

L –litre

Wt% - weight percent

10 All temperatures are in Celsius degrees (°C)

Example 1

Preparation of DTPA-bis(anhydride)

15

DTPA (100 g, 0.25 mole), acetic anhydride (various amounts), and pyridine (various amounts) were combined in a 1 L, 3-necked flat-bottomed reactor fitted with a thermometer, a mechanical stirrer, and reflux condenser cooled with cold water. The reactor was fitted with a water jacket, and the temperature in the jacket was
20 controlled by a water bath. The mixture was heated with stirring to 70°C. Samples were taken from the reaction mixture at 0.5, 1, 2, 3, 4, and 5 h after the temperature had reached 70°C. All samples were filtered on a Büchner funnel, washed with acetonitrile and dried at vacuum. All samples and a sample of the end product were analysed by NIR with respect to DTPA content. After 10 h the reaction mixture was
25 cooled to room temperature. The mixture was then filtered on a Büchner funnel and washed with approximately 70 ml acetonitrile. The product was collected and dried with vacuum at 50°C.

30

Example 2

Effect of pyridine and acetic anhydride concentration

Experiments following the procedure of Example 1 were carried out to optimise the reaction with respect to the amount of pyridine and acetic anhydride on the reaction
35 rate and DTPA content in the final product (Tables 1 and 2). We assumed a first order reaction when calculating the reaction rate.

Effect of pyridine concentration:

From the data of table 1 it will be seen that the reaction rate was decreasing with decreasing pyridine concentration. However, at a reaction time of 10 h the conversion was completed for pyridine concentration down to 1.0 mole/mole DTPA.

- 5 For the experiment with the lowest pyridine concentration of 0.5 mole/mole DTPA the conversion was not completed after 10 h, and thus, the concentration of DTPA was significantly higher for this experiment. A further decrease of pyridine may be possible if the reaction time is prolonged and/or the temperature is raised.

10 Table 1.

Reaction rate and purity for different pyridine concentration levels. Concentration of acetic anhydride was constant for all experiments (3.0 mole acetic anhydride / mole DTPA)

Pyridine amount (mole/mole DTPA)	Reaction rate (h ⁻¹)	DTPA content (wt%)
8.1	1.3	0.85
3.0	0.91	0.82
1.0	0.63	0.71
0.5	0.39	2.24

15

Effect of acetic anhydride concentration:

The effect of variations in the acetic anhydride concentration is illustrated in Table 2.

- 20 The optimised acetic anhydride concentration seems to be 3 moles/mole DTPA. The stoichiometric amount in the conversion of DTPA to DTPA-bis(anhydride) is 2 mole/mole DTPA, but it seems that acetic anhydride should be added in slightly excess. However, a high excess of acetic anhydride leads to a decreased reaction rate, and thereby, higher concentration of the raw material in the product. This effect is probably because high concentration of acetic anhydride leads to a dilution effect
- 25 for the reagents DTPA and pyridine. This dilution effect is observed also for higher pyridine concentrations, but it seems to be most pronounced for low pyridine concentrations.

30

Table 2.

Reaction rate and purity for different acetic anhydride concentration levels.

Concentration of pyridine was constant for all experiments (1.0 mole pyridine / mole DTPA)

Acetic anhydride concentration (mole/mole DTPA)	Reaction rate (h^{-1})	DTPA content (wt%)
7.4	0.39	2.37
5.3	0.45	3.60
3.0	0.63	0.71
2.1	0.54	3.60

Table 3

Summary of the concentration of impurities in the product produced at a molar ratio of 1 mole DTPA to 1 and 10 mole pyridine and 3 moles acetic anhydride where the reaction is run according to Example 1. DTPA-MMA was measured by ^1H NMR.

Concentration of impurities for two pyridine concentration levels

Molar ratio DTPA:Pyridine	DTPA (wt%)	DTPA-MMA (wt%)	Pyridine (ppm)
1.0:10.0	0.71	2.0	0.12
1.0:1.0	1.03	4.4	0.0

Example 3**Effect of temperature**

When the reaction of example 1 was run at 80°C the reaction rate showed a significant increase. At 80°C the reaction rate was 2.0 h^{-1} , whereas the rate was 0.63 h^{-1} when the reaction was run at 70°C . The concentration of impurities was slightly lower for the reaction run at 80°C .

Example 4Synthesis of DTPA-BMA from DTPA-bis(anhydride)

Some of the batches of DTPA-bis(anhydride) were used to produce DTPA-BMA, which is the next step in the process for the production of Gadodiamid, the drug substance of Omniscan™. Table 4 presents the results for the quality parameters of DTPA-BMA from DTPA-bis(anhydride) produced at three different content levels of pyridine. Decreased pyridine content generally gave similar content of the impurities, and all these impurities were inside the specification for DTPA-BMA.

10 Table 4.

Concentration of raw material for the DTPA-bis(anhydride) formation (mole/mole DTPA)		HPLC concentration (area %)		
Pyridine	Acetic anhydride	DTPA	DTPA-MMA	DTPA-BMA
10.0	3.7	0.1	1.05	98.8
3.0	3.0	0.1	0.6	99.3
1.0	3.0	0.1	0.4	99.3



Claims:

1. Process for the production of DTPA-bis(anhydride) *characterized in* that DTPA is
5 reacted with acetic anhydride in pyridine under elevated temperature and that the
molar amount of pyridine is equal to or less than 6 times the molar amount of DTPA.
2. Process of claim 1 wherein the molar amount of pyridine is equal to or less than 3
times the molar amount of DTPA.
- 10 3. Process of claim 1 wherein the molar amount of pyridine is equal to or less than 1
time the molar amount of DTPA.
4. Process of claim 1 wherein the molar amount of pyridine is at least 0.5 times the
15 molar amount of DTPA.
5. Process of claims 1 to 3 wherein the molar amount of pyridine
is approximately the same as the molar amount of DTPA.
- 20 6. Process of claims 1 to 5 wherein the molar amount of acetic anhydride is in excess
of the molar amount of DTPA.
7. Process of claim 6 wherein the molar amount of acetic anhydride is more than 7
times the molar amount of DTPA.
- 25 8. Process of claim 6 wherein the molar amount of acetic anhydride is more than 5
times the molar amount of DTPA.
9. Process of claim 6 wherein the molar amount of acetic anhydride is more than 3
30 times the molar amount of DTPA.
10. Process of claim 6 wherein the molar amount of acetic anhydride is more than 2
times the molar amount of DTPA.
- 35 11. Process of claim 6 wherein the molar amount of acetic anhydride is about 3 times
the molar amount of DTPA.

12. Process of claims 1 to 3, 5 and 9 to 11 wherein the molar amount of acetic anhydride is about 3 times the molar amount of DTPA and the amount of pyridine is approximately the same as the molar amount of DTPA.

5 13. Process of the preceding claims wherein the reaction temperature is above 65°C.

14. Process of the preceding claims wherein the reaction temperature is above 70°C.

10 15. Process of the preceding claims wherein the reaction temperature is at 80°C or above.

16. Process of claims 1 to 3, 5 and 9 to 11 and 16 wherein the molar amount of acetic anhydride is about 3 times the molar amount of DTPA, the amount of pyridine is approximately the same as the molar amount of DTPA and wherein the reaction
15 temperature is approximately 80°C.


17. DTPA-bis(anhydride) *characterized in* being produced by the process of the preceding claims.

20

25

30

35



Abstract

- 5 Process for the production of DTPA-bis(anhydride) by reacting DTPA with acetic anhydride in pyridine under elevated temperature wherein the molar amount of pyridine is equal to or less than 6 times the molar amount of DTPA.



Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/NO04/000389

International filing date: 16 December 2004 (16.12.2004)

Document type: Certified copy of priority document

Document details: Country/Office: NO
Number: 20035745
Filing date: 19 December 2003 (19.12.2003)

Date of receipt at the International Bureau: 11 February 2005 (11.02.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.